滤泡性淋巴瘤中GNA13蛋白的分析及其与不良预后的关系

免疫组化抗体神器

好评必备! 免费下载

  --本文经《美国外科病理学杂志》授权发布,其他媒体转载或引用须经《美国外科病理学杂志》同意,否则追究法律责任。
 
  GNA13是一种与肿瘤增殖、浸润、转移和迁移相关的G蛋白。GNA13的基因组改变在滤泡性淋巴瘤(follicular lymphoma,FL)中较为常见。本研究采用组织芯片及免疫组化技术,检测了167例FL中GNA13的表达情况并评估其临床意义。其中26例GNA13阳性(15.6%),141例GNA13阴性(84.4%)。与GNA13阴性组相比,GNA13阳性组病例的疾病早期进展(在2年内发现)发生率较高(P=0. 03)。而组织学分级、BCL2-IGH易位、免疫组化表型和滤泡性淋巴瘤国际预后指数等其他临床病理因素方面均无显著差异。此外,GNA13阳性病例的总生存期和无进展生存期均低于GNA13阴性病例(分别为P=0. 009和0.005)。在多变量分析中,GNAI3阳性是总生存期和无进展生存期的不良预后因素。因此,GNA13蛋白的表达是独立的预后因素,可能影响FL的疾病进展。
Am J Surg Pathol 2018;42:1466-1471
美国外科病理学杂志中文版2019年第二期摘要NO.8
(李晶晶  翻译  刘斌  审校)
  The American Journal of Surgical Pathology中文版声明:
  ©2018 Wolters Kluwer Health
  The material is published by Wolters Kluwer Health with the permission of American Journal of Surgical Pathology.No part of this publication may be reproduced in any form,stored in a retrieval system or transmitted in any form,by any means,without prior written permission from Wolters Kluwer Health.Opinions expressed by the authors and advertisers are not necessarily those of the American Journal of Surgical Pathology, its affiliates,or of the Publisher.The American Journal of Surgical Pathology,its affiliates,and the Publisher disclaim any liability to any party for the accuracy,completeness,efficacy,or availability of the material contained in this publication (including drug dosages) or for any damages arising out of the use or non-use of any of the material contained in this publication.
  Although advertising material is expected to conform to ethical (medical) standards,inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
 
  【本文经《美国外科病理学杂志》授权发布,其他媒体转载或引用须经《美国外科病理学杂志》同意 ,否则追究法律责任;所有文章仅供公益交流,不代表本站立场。欢迎提供素材、资料等,投稿邮箱: tougao@91360.com,一经采纳将给予稿费】
责任编辑: 奶糖
0 0 0

扫一扫下载91360客户端